Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Will Acquire Orion Labs To Reach Australian Market

This article was originally published in PharmAsia News

Executive Summary

Perrigo's pending $49 million acquisition of Orion Laboratories marks the private labeler's entrance into the promising Australian OTC market and adds a "beachhead" for the firm's continued global expansion, analysts say

You may also be interested in...



Perrigo Strives To Stand Out Against Incoming Private Label Competition

Even as Perrigo products face the prospect of increasingly crowded segments, the company likes where it stands among private label competition

Perrigo divests Israel consumer biz

Allegan, Mich.-based Perrigo Company signed an agreement to sell its Israel Consumer Products business and related production assets to Emilia Group, a subsidiary of O. Feller Holdings Ltd., for approximately $54 mil. The transaction will close in the first quarter of 2010, the firm says. The divestment "execut[es] our previously announced decision to exit this business," Perrigo Chairman and CEO Joseph C. Papa said in a statement. Perrigo will provide distribution and support services for the related U.S. private label cosmetics business for 12 months after the close of the transaction, release states

Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy

Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel